Form 4: Masimo EVP Exercises Options, Sells Shares Under 10b5-1 Plan

Masimo's EVP of Operations and Clinical Research, Anand Sampath, exercised stock options and subsequently sold a portion of his common stock holdings under a pre-arranged 10b5-1 plan.

Summary

• Anand Sampath, Executive Vice President of Operations & Clinical Research at Masimo Corp (MASI), reported transactions on January 28, 2026.
• Sampath exercised Non-Qualified Stock Options to acquire 30,000 shares of common stock at an exercise price of $37.84 per share.
• Following the option exercise, Sampath sold a total of 18,680 shares of common stock in multiple transactions.
• The sales were executed at weighted average prices ranging from $136.56 to $138.09 per share.
• All reported sales were conducted pursuant to a Rule 10b5-1 Sales Plan established on September 12, 2025.
• After these transactions, Sampath's direct beneficial ownership of Masimo common stock stands at 40,909 shares.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While it involves insider selling, the pre-arranged 10b5-1 plan and the executive's retained significant holdings mitigate any negative sentiment, suggesting planned financial management rather than a lack of confidence.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 Sales Plan, indicating planned personal financial management rather than a reaction to new company-specific negative information.
• The executive realized significant gains from the exercise of options, with sale prices substantially higher than the exercise price of $37.84.
• Anand Sampath retains a substantial holding of 40,909 shares of Masimo common stock, demonstrating continued alignment with shareholder interests.

Negatives

• The sale of 18,680 shares by a key executive could be interpreted by some as a reduction in insider exposure, although mitigated by the 10b5-1 plan.

Future Outlook

The filing indicates that the sales were part of a Rule 10b5-1 Sales Plan, which is a pre-arranged trading plan designed to allow insiders to sell shares without being accused of trading on material non-public information. This suggests a planned approach to liquidity and diversification rather than a reaction to immediate future expectations.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those involving option exercises and subsequent sales, are common in the executive compensation landscape across various industries. The use of a Rule 10b5-1 plan is a standard practice for executives to manage their equity holdings in a compliant manner, providing transparency and mitigating concerns about opportunistic trading. This type of transaction is typical for a seasoned executive diversifying their portfolio.

Comparison to Industry Standards

• The use of a Rule 10b5-1 plan for executive stock sales is a widely accepted corporate governance practice, aligning with best practices seen in companies like Apple (AAPL) and Microsoft (MSFT) where executives regularly use such plans for planned share dispositions.
• The significant gain realized from the option exercise (sale prices over 3x the exercise price) is indicative of long-term stock appreciation, a common outcome for executives in successful growth companies within the medical technology sector, similar to those observed at Medtronic (MDT) or Abbott Laboratories (ABT) over extended periods.

Stakeholder Impact

• Shareholders: The sale of shares by an executive could be viewed as a slight reduction in insider alignment, but the pre-arranged nature and retained holdings temper this. The significant profit realized by the executive reflects positive stock performance, which benefits all shareholders.
• Employees: No direct impact on employees is indicated by this filing.

Key Dates

Recommendation

The filing details a planned insider sale under a 10b5-1 plan, which is a routine event for executive compensation and personal financial planning. While the volume of shares sold is notable, the pre-arranged nature and the executive's continued substantial ownership do not signal a fundamental change in the company's outlook that would warrant a 'buy' or 'sell' recommendation based solely on this filing. Investors should 'hold' and consider this transaction as part of normal executive compensation and diversification activities.

Keywords

Masimo, MASI, Insider Trading, Form 4, Stock Options, 10b5-1 Plan, Executive Compensation, Share Sale, Anand Sampath